Press and Downloads

12/15/2023

Investors Fundraiser 2023

Donation from Bioventure to UMG and Harzer Sonnenzwerge e.V. – support for children suffering from cancer

10/27/2022

Bioventure invests in curing HIV

Bioventure invests as lead investor in PROVIREX Genome Editing Therapies GmbH, a Hamburg-based biotech company focusing on infectious diseases, primarily using a genome editing technology newly developed by its founders.

Press release 2023-12-15 Investors Fundraiser 2023 in favor of UMG and Harzer Sonnenzwerge
Press release 2022-10-27 Provirex establishes therapy hub for HIV cure at Science City Hamburg Bahrenfeld

Downloads

BIOVENTURE_Dr_Erik_Hoppe.jpg 1 MB
BIOVENTURE_Nico_Straub.jpg 3 MB
Logo_Bioventure.jpg 168 KB
Logo_Bioventure_rgb.eps 816 KB
Logo_Bioventure_rgb.pdf 308 KB